Effective miRNAs in the drug resistance ofpaclitaxel-resistant breast cancer cell lines

Introduction: Breast cancer is one of the most common invasivemalignancies in women worldwide. Paclitaxel is recognizedas first-line therapy in the treatment of BC. However, itseffectiveness is often limited by the development of drug resistance,a major obstacle in clinical applications and a major causeof mortality associated with treatment failure. In recent years,some miRNAs have been reported to be involved in the modulationof drug resistance-related pathways Hence, paclitaxel resistance(PR) is the main obstacle in the treatment of BC.Materials and Methods: Databases such as Embase, Web ofScience, PubMed and The Cochrane Library were searchedfrom the database establishment to April ۲۰۲۳ to collect in vivo,and clinical studies of microRNA and drug resistance of paclitaxel-resistant breast cancer. Then the literature was screenedand the data were extracted.Results: Recently, many microRNAs (miRNAs) have beencharacterized and identified as indispensable regulators and/orbiomarkers in breast cancer development, including initiation,metastasis, and therapy resistance and different miRNAs areclosely related to tumor initiation, drug resistance, and recurrenceof breast cancer. Mechanisms of PTX action representseveral ways in which PTX affects cellular processes resultingin programmed cell death. miR-۴۵۱ and miR-۱۲۵ are significantlydownregulated in human breast cancer samples and inpaclitaxel-resistant (PR) cells, and overexpression of miR-۲۴ and miR-۵۲۰ induces drug resistance to paclitaxel in breastcancer cells. Aberrant expression of miRNAs can inhibit cellmigration and invasion, promote apoptosis, and cause cell cyclearrest.Conclusion: Based on the main findings detailed above, differentmiRNAs may be considered as important and potentialtargets in the treatment of paclitaxel-resistant breast cancer.

کلیدواژه ها:

breast cancer ، miRNAs ، drug resistance ، paclitaxelresistant